Skip to main content
. 2021 Feb;103:562–567. doi: 10.1016/j.ijid.2020.11.192

Table 2.

Characteristics of study participants initiated on Isoniazid Preventive Therapy.

Covariate IPT status
Total
IPT-No IPT-Yes
Sex
Male 45,539(31.90%) 6852(28.59%) 52,391
Female 97,200(68.10%) 17,118(71.41%) 114,318



Age (Years):
0−9 6987(4.90%) 533(2.22%) 7520
10−19 6637(4.65%) 705(2.94%) 7342
20−24 14,164(9.92% 1720(7.18%) 15,884
25−49 101,441(71.07%) 18,552(77.40%) 119,993
+50 13,501(9.46%) 2460(10.26%) 15,961



Functional status
Ambulatory 4844(3.41% 516(2.16%) 5360
Bedridden 1226(0.86%) 140(0.59%) 1366
Walking 136,039(95.73% 23,207(97.25%) 159,246



ART status
ART-No 90,009(63.52%) 17,210(72.23%) 107,219
ART-Yes 51,690(36.48%) 6584(27.67%) 58,274



Nutritional status
Normal 124,761(91.79%) 21,559(93.31%) 146,320
Moderate 9558(7.03%) 1387(6.00%) 10,945
Severe 1596(1.17%) 159(0.69%) 1755



BMI
Underweight 16,376(18.05%) 2630(14,85%) 19,006
Normal 50,879(56.08% 102,020(57.59%) 61,081
Overweight 15,989(17.62%) 3327(18.78%) 19,316
Obesity 7479(8.24%) 1557(8.79%) 9036



WHO clinical stage
Stage I 52,411(37.20%) 7780(32.87%) 60,191
Stage II 32,948(23.39%) 6304(26.63%) 39,252
Stage III 44,526(31.60%) 8141(34.39%) 52,667
Stage IV 11,008(7.81%) 1447(6.11%) 12,455
Enrolment Year
2012 25,781(18.06%) 4315(18.00%) 30,096
2013 28,045(19.65%) 4930(20.57%) 32,975
2014 29,880(20.93%) 5464(22.80%) 35,344
2015 27,297(19.12%) 4.750(19.82%) 32,047
2016 31,736(22.23%) 4511(18.82%) 36,247



Health Facility level
Dispensary 56,931(39.88%) 5934(24.76%) 62,865
Health Center 38,236(26.79%) 6325(26.39%) 44,561
Hospital 47,572(33.33%) 11,711(48.86%) 59,283



ARV adherence
Good 27,611(98.48%) 5590(98.98%) 31,201
Poor 426(1.52%) 37(1.02%) 463



Region
Dar es Salaam 102,233(71.62%) 18,150(75.12%) 120,383
Iringa 17,176(12.03%) 986(4.11%) 18,162
Njombe 23,330(16.34%) 4834(20.17% 28,164



Health Facility ownership
Private 41,559(29.12% 3750(15.64%) 45,309
Public 101,180(70.88%) 20,220(84.36%) 121,400